Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated ...

Abbott Laboratories is forecasting profit for 2025 in line with Wall Street’s estimates as the health care company said ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott reported fourth-quarter results that missed the consensus sales forecast — but medical device sales remain a bright ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

Abbott's Q4 sales reached $10.97 billion, with 8.8% organic growth. EPS met expectations at $1.34, driven by strong ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

For the current quarter ending in March, Abbott expects its per-share earnings to range from $1.05 to $1.09. The company expects full-year earnings in the range of $5.05 to $5.25 per share.

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...